Back to overview

Transcranial ultrasound enhanced trombolysis

English title Transcranial ultrasound enhanced trombolysis
Applicant Baumgartner Ralf
Number 108476
Funding scheme Project funding (Div. I-III)
Research institution Neurologische Klinik Universitätsspital Zürich
Institution of higher education University of Zurich - ZH
Main discipline Neurophysiology and Brain Research
Start/End 01.09.2005 - 31.12.2010
Approved amount 260'000.00
Show all

Keywords (3)

Stroke; Thrombolysis; Ultrasound assisted thrombolysis

Lay Summary (English)

Lay summary
Stroke is the leading cause of permanent disability, and the second most frequent cause of death worldwide. Thrombolysis with intravenous (iv) tissue plasminogen activator (t-PA) is the only effective and approved therapy for acute ischemic stroke. The most frequent cause of ischemic stroke is thrombosis of the middle cerebral artery (MCA). Preliminary in vitro, animal and human studies suggest that ultrasound accelerates thrombolysis induced by t-PA, and recanalization of acute MCA occlusion due to thrombolysis is an independent predictor of good clinical outcome.Thus, insonation of an occluded MCA through the temporal bone in stroke patients who are treated with iv t-PA might enhance recanalization and improve clincal outcome. The present prospective, randomized, controlled multicenter pilot study will investigate the safety and efficacy of continuous 1-hour insonation of the occluded MCA with 2 MHz transcranial color duplex sonography in patients with ischemic stroke treated with iv t-PA within 3 hours after symptom onset. It is planned to randomize 400 patients in 6 swiss centers during an enrolment period of 33 months with an individual follow-up of 3 months. The study endpoints include safety and efficacy assessment. The primary safety endpoint is to determine the rate of symptomatic intracranial hemorrhage (ICH) in both treatment groups. The primary efficacy endpoint is to determine whether a good functional outcome (modified Rankin scale (mRS) score of 0-2) differs between both treatment groups. Secondary endpoints include (1) asymptomatic ICH occurring during or within the first 24-48 hours after t- PA infusion, (2) early clinical recovery by >9 National Institute of Health Stroke Scale (NIHSS) points or dramatic recovery (total NIHSS score<4) at 24-48 hours after t-PA infusion, (3) mean mRS score at 90 days after t-PA infusion, (4) death occurring during the study period, and (5) recanalization at 24-48 hours after t-PA infusion.
Direct link to Lay Summary Last update: 21.02.2013

Responsible applicant and co-applicants


Associated projects

Number Title Start Funding scheme
112685 Role of wall stress in the pathogenesis of spontaneous dissection of the cervical carotid artery 01.02.2007 Project funding (Div. I-III)